SCHEMBL9923267

SCHEMBL9923267

CNc1cccc(C2=NN(c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3C)C(=O)C2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.38
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
TP53 P04637 3/20 0.36
LMNA P02545 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 2/20 0.34
GAA P10253 2/20 0.34
ALDH1A1 P00352 1/20 0.34
P2RY12 Q9H244 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
CA12 O43570 2/20 0.33
CA9 Q16790 2/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923269 0.92 CNR1 (0.37) CNR1BRD4CREBBPTP53LMNA
SCHEMBL14113622 0.92 CNR1 (0.41) CNR1BRD4CREBBPTP53LMNA
SCHEMBL13182766 0.92 BRD4 (0.39) BRD4CREBBPLMNAMEN1KMT2A
SCHEMBL14228356 0.91 GAA (0.40) CNR1BRD4CREBBPTP53LMNA
SCHEMBL9923266 0.89 CNR1 (0.40) CNR1BRD4CREBBPTP53LMNA
SCHEMBL9923270 0.86 TP53 (0.39) CNR1BRD4CREBBPTP53LMNA
SCHEMBL9923268 0.85 TP53 (0.36) CNR1BRD4CREBBPTP53LMNA
SCHEMBL12161729 0.85 P2RY12 (0.42) CNR1TP53LMNAMEN1KMT2A
SCHEMBL14228580 0.84 KMT2A (0.38) CNR1BRD4CREBBPLMNAMEN1
SCHEMBL12161733 0.83 P2RY12 (0.46) CNR1TP53LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 CNR1 253/4885BRD4 3064/4885CREBBP 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.